Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).
06-18-2020 | ADA 2020 | Conference coverage | Video
06-18-2020 | ADA 2020 | Conference coverage | Video
Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).